Munich Re stock: JPMorgan turns cautious before Q3 results

Published on 11/09/2026 at 18:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Munich Re stock traded at 566.40 euros in late Monday trading. JPMorgan turned cautious ahead of the reinsurer's final third-quarter results.

What investors should watch

JPMorgan lowered its rating to Neutral while leaving the price target unchanged.
Munich Re lifted its full-year profit guidance after a strong preliminary third quarter.
Final third-quarter results and management commentary are scheduled for November 12.

Munich Re, DE0008430026, Illustration mit AI erstellt.

JPMorgan lowered its rating on Munich Re from Overweight to Neutral on Friday, November 6, 2026, while keeping its price target at 590 euros. Investing.com said the bank expects 2027 to be one of the toughest years in Munich Re's strategic plan, with further margin pressure in property and casualty reinsurance.

At 6:14 p.m. CET on Monday, November 9, Munich Re stock traded at 566.40 euros on Lang & Schwarz, 0.07 percent above the Xetra close of Monday, November 9. The quote was 2.85 percent below the 583.00 euros reported in the relevant November 4 article, a separate comparison from the daily Xetra move.

Profit outlook meets renewal pressure

Munich Re raised its 2026 net profit guidance from 6.3 billion euros to 6.6 billion euros on October 23 after reporting a preliminary third-quarter net profit of approximately 1.7 billion euros. The result exceeded the 1.479 billion euro consensus from 13 analysts, according to the company's October 23 release.

Munich Re attributed the performance to operating strength across all business segments, lower-than-expected major losses in property and casualty reinsurance and a strong investment result in reinsurance. The group reported a nine-month net result of 5.7 billion euros.

November 12 becomes the next test

The final third-quarter figures are scheduled for Thursday, November 12, 2026. Investors will be watching whether the confirmed earnings support the raised annual target and how management assesses pricing and margins ahead of the 2027 renewal round.